Clinical Trial Update: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib in combination with rituximab for indolent mantle cell lymphoma is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING